Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (06) : 552-556     DOI: 10.3971/j.issn.1000-8578.2022.21.1370
Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma
Department of Radiology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
Download: PDF(3655 KB)   ( 25 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Primary hepatocellular carcinoma (HCC) is the sixth most common malignant tumor in the world, and ranks third in tumor-related deaths. The incidence and mortality of HCC in China are among the top five in both men and women, and are increasing year by year, while less than 30% of patients can be surgically resected. With the continuous development of medical technology, interventional therapy has played a key role in the treatment of HCC. This article reviews the latest progress of interventional therapy such as transarterial chemoembolization, transarterial radioembolization, radiofrequency ablation and microwave ablation, as well as interventional therapy combined with molecular targeted therapy and immunotherapy.
Keywords Hepatocellular carcinoma      Interventional therapy      Transarterial chemoembolization      Transarterial radioembolization      Radiofrequency ablation      Microwave ablation     
ZTFLH:  735.7  
Issue Date: 16 June 2022
 Cite this article:   
ZHOU Shi. Progress in Locoregional Interventional Therapy of Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 552-556.
E-mail this article
E-mail Alert
Articles by authors
[1] Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet,
2018, 391(10127): 1301-1314.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA
Cancer J Clin, 2019, 69(1): 7-34.
[3] Wu JY, Yin ZY, Bai YN, et al. Lenvatinib Combined with Anti-
PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization
for Unresectable Hepatocellular Carcinoma: A Multicenter
Retrospective Study[J]. J Hepatocell Carcinoma, 2021, 8:
[4] Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line
Therapy in Patients With Advanced Hepatocellular Carcinoma in
KEYNOTE-240: A Randomized, Double-Blind, Phase Ⅲ Trial[J].
J Clin Oncol, 2020, 38(3): 193-202.
[5] 中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南
(2022年版)[J]. 肿瘤防治研究, 2022, 49(3): 251-276. [National
Health Commission of the People’s Republic of China.Standardi
zation for diagnosis and treatment of primary hepatic carcinoma
(2022 Edition)[J]. Zhong Liu Fang Zhi Yan Jiu, 2022, 49(3): 251-
[6] Galle PR, Tovoli F, Foerster F, et al. The treatment of intermediate
stage tumours beyond TACE: From surgery to systemic
therapy[J]. J Hepatol, 2017, 67(1): 173-183.
[7] Wang TC, An TZ, Li JX, et al. Development and Validation of
a Predictive Model for Early Refractoriness of Transarterial
Chemoembolization in Patients with Hepatocellular Carcinoma[J].
Front Mol Biosci, 2021, 8: 633590.
[8] Finn R, Ikeda M, Zhu A, et al. LBO09-A phase 1 b study of
lenvatinib plus pembrolizumab in unresectable hepatocellular
carcinoma[J]. J Hepatol, 2020, 73(Suppl1): S120-S121.
[9] Facciorusso A. Drug-eluting beads transarterial chemoembolization
for hepatocellular carcinoma: Current state of the art[J]. World J
Gastroenterol, 2018, 24(2): 161-169.
[10] Lee EW, Khan S. Recent advances in transarterial embolotherapies
in the treatment of hepatocellular carcinoma[J]. Clin Mol Hepatol,
2017, 23(4): 265-272.
[11 ] Shi Q, Chen D, Zhou C, et al. Drug-Eluting Beads versus
Lipiodol Transarterial Chemoembolization for the Treatment
of Hypovascular Hepatocellular Carcinoma: A Single-Center
Retrospective Study[J]. Cancer Manag Res, 2020, 12: 5461-5468.
[12] Shen L, Zhang Y, Guo Y, et al. 987P A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts)
with the first-line (1L) unresectable hepatocellular carcinoma
(uHCC)[J]. Ann Oncol, 2020, 31: S690-S691.
[13] He M, Li Q, Zou R, et al. Sorafenib Plus Hepatic Arterial Infusion
of Oxaliplatin, Fluorouracil, and Leucovorin vs. Sorafenib Alone
for Hepatocellular Carcinoma with Portal Vein Invasion: A
Randomized Clinical Trial[J]. JAMA Oncol, 2019, 5(7): 953-960.
[14] He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy
using mFOLFOX versus transarterial chemoembolization for
massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1): 83.
[15] Nault JC, Sutter O, Nahon P, et al. Percutaneous treatment of
hepatocellular carcinoma: State of the art and innovations[J]. J
Hepatol, 2018, 68(4): 783-797.
[16] Hocquelet A, Aubé C, Rode A, et al. Comparison of no-touch
multi-bipolar vs. monopolar radiofrequency ablation for small
HCC[J]. J Hepatol, 2017, 66(1): 67-74.
[17] English K, Brodin NP, Shankar V, et al. Association of Addition
of Ablative Therapy Following Transarterial Chemoembolization
with Survival Rates in Patients with Hepatocellular Carcinoma[J].
JAMA Netw Open, 2020, 3(11 ): e2023942.
[18] Shi F, Wu M, Lian SS, et al. Radiofrequency Ablation Following
Downstaging of Hepatocellular Carcinoma by Using Transarterial
Chemoembolization: Long-term Outcomes[J]. Radiology, 2019,
293(3): 707-715.
[19] Yuan H, Liu F, Li X, et al. Angio-CT-Guided Transarterial
Chemoembolization Immediately in Combination with
Radiofrequency Ablation for Large Hepatocellular Carcinoma[J].
Acad Radiol, 2019, 26(2): 224-231.
[20] Glassberg MB, Ghosh S, Clymer JW, et al. Microwave ablation
compared with radiofrequency ablation for treatment of
hepatocellular carcinoma and liver metastases: a systematic review
and meta-analysis[J]. Onco Targets Ther, 2019, 1 2: 6407-6438.
[21] 杨立新, 赵天慧, 魏强, 等. 超声引导微波消融联合TACE治疗晚期
原发性肝癌的疗效及对免疫功能的影响[J]. 中国超声医学杂志,
2020, 36(5): 428-432. [Yang LX, Zhao TH, Wei Q, et al. Curative
Effect of Ultrasonic Guided Microwave Ablation Combined with
TACE in the Treatment of Advanced Primary Liver Cancer and Its
Influence on Immune Function[J]. Zhongguo Chao Sheng Yi Xue
Za Zhi, 2020, 36(5): 428-432.]
[22] Hu H, Chen GF, Yuan W, et al. Microwave ablation with
chemoembolization for large hepatocellular carcinoma in patients
with cirrhosis[J]. Int J Hyperthermia, 2018, 34(8): 1351-1358.
[23] Kim R, Kang TW, Cha DI, et al. Percutaneous cryoablation for
perivascular hepatocellular carcinoma: Therapeutic efficacy and
vascular complications[J]. Eur Radiol, 2019, 29(2): 654-662.
[24] Sutter O, Calvo J, N'Kontchou G, et al. Safety and Efficacy of
Irreversible Electroporation for the Treatment of Hepatocellular
Carcinoma Not Amenable to Thermal Ablation Techniques: A
Retrospective Single-Center Case Series[J]. Radiology, 2017,
284(3): 877-886.
[25] Kudo M, Ueshima K, Ikeda M, et al. Randomized, open
label, multicenter, phase Ⅱ trial comparing transarterial
chemoembolization (TACE) plus sorafenib with TACE alone in
patients with hepatocellular carcinoma (HCC): TACTICS trial[J].
J Clin Oncol, 2018, 36(4_suppl): 206.
[26] Lu J, Guo JH, Zhu HD, et al. Safety and Efficacy of Irradiation
Stent Placement for Malignant Portal Vein Thrombus Combined
with Transarterial Chemoembolization for Hepatocellular
Carcinoma: A Single-Center Experience[J]. J Vasc Interv Radiol,
2017, 28(6): 786-794.
[27] Khan KA, Kerbel RS. Improving immunotherapy outcomes with
anti-angiogenic treatments and vice versa[J]. Nat Rev Clin Oncol,
2018, 15(5): 310-324.
[28] Zhu K, Huang J, Lai L, et al. Medium or Large Hepatocellular
Ca r c inoma : Sor a f enib Combined wi th Tr ans a r t e r i a l
Chemoembolization and Radiofrequency Ablation[J]. Radiology,
2018, 288(1): 300-307.
[29] Kudo M. A New Treatment Option for Intermediate-Stage
Hepatocellular Carcinoma with High Tumor Burden: Initial
Lenvatinib Therapy with Subsequent Selective TACE[J]. Liver
Cancer, 2019, 8(5): 299-311 .
[30] Liu J, Xie S, Duan X, et al. Assessment of efficacy and safety
of the transcatheter arterial chemoembolization with or without
apatinib in the treatment of large hepatocellular carcinoma[J].
Cancer Chemother Pharmacol, 2020, 85(1): 69-76.
[31] Pinato DJ, Murray SM, Forner A, et al. Trans-arterial
chemoembolization as a loco-regional inducer of immunogenic
cell death in hepatocellular carcinoma: implications for
immunotherapy[J]. J Immunother Cancer, 2021, 9(9): e003311 .
[32] Gerbes A, Zoulim F, Tilg H, et al. Gut roundtable meeting paper:
selected recent advances in hepatocellular carcinoma[J]. Gut,
2018, 67(2): 380-388.
[33]Duffy AG, Ulahannan SV, Makorova-Rusher O, et al.
Tremelimumab in combination with ablation in patients with
advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3):
[34] Huang Y, Kim BYS, Chan CK, et al. Improving immune-vascular
crosstalk for cancer immunotherapy[J]. Nat Rev Immunol, 2018,
18(3): 195-203.
[35] Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib
Plus Pembrolizumab in Patients With Unresectable Hepatocellular
Carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
[36] Lau WY, Lai EC. Salvage surgery following downstaging of
unresectable hepatocellular carcinoma-a strategy to increase
resectability[J]. Ann Surg Oncol, 2007, 14(12): 3301-3309.
[37] Tabone M, Calvo A, Russolillo N, et al. Downstaging unresectable
hepatocellular carcinoma by radioembolization using 90-yttrium
resin microspheres: a single center experience[J]. J Gastrointest
Oncol, 2020, 11 (1): 84-90.
Related articles from Frontiers Journals
[1] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[2] ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun. Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 655-661.
[3] ZHOU Silei, SUN Guanqun, ZENG Tanlun, CHENG Zhuo, LIANG Xijun. Expression and Prognostic Value of CK2α' in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 662-666.
[4] JIANG Mingting, HUANG Jing, ZHENG Shuping. Effects of Pin1 on Proliferation and Apoptosis of HepG2 Cells Under Endoplasmic Reticulum Stress[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 575-580.
[5] XU Huan, WANG Guangli, LI Tingming, WANG Wei, DONG Dandan. Transcriptome Analysis of Inhibitory Effect of Astaxanthin Against HepG2 Cell Lines[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 581-584.
[6] WANG Jue, JIN Zongrui, WANG Wei, YI Qilin, WANG Jilong, ZHU Hai, XU Banghao, GUO Ya, WEN Zhang. Prognostic Role of Immune-related Genes in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 599-605.
[7] XU Shasha, HAN Xingmin. Research Advances on Application of 18F-FDG PET/CT in Clinical Diagnosis and Treatment of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 384-389.
[8] CUI Honglei, ZHANG Xiaodan, GUO Danfeng, YAN Zhiping, GUO Wenzhi, ZHANG Shuijun. Expression of ENO3 and Its Effect on Sensitivity of Hepatocellular Carcinoma Cells to Oxaliplatin[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 438-443.
[9] ZHOU Yongjie, WANG Zhengfeng, YAN Jun, WANG Haiping, XU Wen, ZHOU Wence. Value of Preoperative Lactate Dehydrogenase-to-Albumin Ratio Combined with AFP in Evaluating Prognosis of Patients with Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 347-351.
[10] TAO Changcheng, ZHANG Kai, RONG Weiqi, WU Jianxiong. Research Progress of Early Recurrence and Cut-off Time of Hepatocellular Carcinoma after Radical Hepatectomy[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 359-363.
[11] ZHANG Haodong, WEI Fengxian, ZHANG Chunfang, XU Xiaodong. Clinical Value of Platelet and Its Parameters Combined with Tumor Markers in Preoperative Differentiation of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 213-218.
[12] CHEN Long, LIU Yujie, TIAN Suqing, WANG Cuiying, HE Donglei. Curative Effect of Lenvatinib Combined with Locoregional Therapy on PD-L1-positive Hepatocellular Carcinoma Patients with Type Ⅰ-Ⅲ Portal Vein Tumor Thrombus According to Cheng’s Classification[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 53-57.
[13] PANG Kangqing, MA Hongde, YANG Rulei, PANG Guohong. Expression and Clinical Significance of Serum PTX3 in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1078-1081.
[14] SONG Yanzhou, ZHANG Kun, CHEN Qijun, WEI Wenping, ZHAO Xin, LI Zhiwei, LI Wei. Experiment on Inhibiting NEK7 to Promote Apoptosis of Hepatocellular Carcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 929-933.
[15] XU Gang, BU Shanshan, WANG Xiushen, GE Hong. Correlation Between cyclin G1 Expression and Efficacy of Radiotherapy on Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2021, 48(10): 958-962.
Full text